Abstract
Background: The purposes of this pilot retrospective observational cohort study are to determine: 1) the safety and efficacy of corneal photovitrification (CPV), a corneal laser procedure, for vision improvement in patients with neovascular age-related macular degeneration (nAMD) and other retinal disorders involving central vision loss, and 2) the correlation between post-treatment (post-treatment (Tx)) best-corrected distance visual acuity (BCDVA) and pre-Tx potential visual acuity (PVA). Methods: BCDVA measurements using ETDRS charts and PVA measurements using Gonzalez-Markowitz PVA charts were analyzed for 72 eyes that received a single CPV treatment. Results: Safety - No clinically significant complications or serious adverse events occurred. Efficacy – Mean BCDVA improved significantly from 20/303 (1.18 log of the minimum angle of resolution (logMAR), 26 letters) at pre-Tx to 20/208 (1.02 logMAR, 34 letters) at 1m post-Tx (p = 0.000001) for a cohort of 57 eyes, improving to 20/198 (1.00 logMAR, 35 letters; 11.6 mean letters gained) at 12m (p = 0.0009) for a cohort of 29 eyes. Mean pre-Tx PVA gains correlated well with mean BCDVA improvements at 1m, 3m, 6m and 12m post-Tx. Conclusions: Subject to a small sample size, the CPV corneal laser procedure is safe and efficacious for vision improvement in patients with nAMD and other retinal disorders involving central vision loss. The pre-Tx PVA correlates well with post-Tx BCDVA; the PVA test may be useful for screening of candidate eyes for CPV treatment and for managing expectations.
Highlights
Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries[1]
The purpose of the present study is to describe the corneal photovitrification (CPV) corneal laser procedure and outcomes of the procedure that provide additional and significant vision improvement in patients with neovascular form of AMD (nAMD) and other retinal disorders involving central vision loss
For treated nAMD eye groups, outcomes are statistically significant at the p
Summary
Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries[1]. The purpose of the present study is to describe the corneal photovitrification (CPV) corneal laser procedure and outcomes of the procedure that provide additional and significant vision improvement in patients with nAMD and other retinal disorders involving central vision loss All of these patients have received and continue to receive standard of care routine treatments such as anti-VEGF injections. A preliminary version of this work was presented, in part, at the Association for Research in Vision and Ophthalmology Annual Meeting on 1–7 May 20214 The purposes of this pilot retrospective observational cohort study are to determine: 1) the safety and efficacy of corneal photovitrification (CPV), a corneal laser procedure, for vision improvement in patients with neovascular age-related macular degeneration (nAMD) and other retinal disorders involving central vision loss, and 2) the correlation between post-treatment (posttreatment (Tx)) best-corrected distance visual acuity (BCDVA) and preTx potential visual acuity (PVA). The pre-Tx PVA correlates well with post-Tx BCDVA; the PVA test may be useful for screening of candidate eyes for CPV treatment and for managing expectations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
